CardioCircle (@CardioCircle) header
CardioCircle (@CardioCircle) profile picture

Cardiology moves fast. CardioCircle cuts through the noise to reveal what matters.

Riyadh, KSA
Joined July 2026
Photo by CardioCircle (@CardioCircle)Photo by CardioCircle (@CardioCircle)Photo by CardioCircle (@CardioCircle)Photo by CardioCircle (@CardioCircle)Photo by CardioCircle (@CardioCircle)Photo by CardioCircle (@CardioCircle)Photo by CardioCircle (@CardioCircle)Photo by CardioCircle (@CardioCircle)Photo by CardioCircle (@CardioCircle)Photo by CardioCircle (@CardioCircle)
๐Ÿšจ๐—ช๐—ผ๐˜‚๐—น๐—ฑ ๐˜†๐—ผ๐˜‚ ๐—ฒ๐—ฑ๐—ถ๐˜ ๐—ฎ ๐—ด๐—ฒ๐—ป๐—ฒ ๐˜๐—ผ ๐—น๐—ผ๐˜„๐—ฒ๐—ฟ ๐˜๐—ฟ๐—ถ๐—ด๐—น๐˜†๐—ฐ๐—ฒ๐—ฟ๐—ถ๐—ฑ๐—ฒ๐˜€? CTX310: one infusion targeting #ANGPTL3; mean triglycerides down 63% at 30 days in ten adults with severe hypertriglyceridemia. The promise is lasting lipid control. The evidence is an uncontrolled phase 1b cohort. Long-term safety and prevention of pancreatitis or cardiovascular events remain unproven. These early findings deserve attention and larger, longer studies. What evidence would you require before considering gene editing in routine lipid care? @CRISPRTX @AHAScience #CardioCircle #CardioX #CardioTwitter #Cardiology #medX #GeneEditing
1
1
65
๐Ÿšจ๐—ช๐—ต๐—ฒ๐—ฟ๐—ฒ ๐˜„๐—ฒ ๐—ฝ๐—ฎ๐—ฐ๐—ฒ ๐—บ๐—ฎ๐˜๐˜๐—ฒ๐—ฟ๐˜€. โžก๏ธOptimPacing strengthens the case for protecting ventricular function from the first implant. ๐ŸŸข With left bundle branch versus right ventricular pacing, the composite of death, heart failure hospitalization, or pacing-induced cardiomyopathy occurred in 16/342 (4.7%) versus 35/343 (10.2%) over a median of 35 months. ๐ŸŸขThe hazard was 59% lower, but early stopping warrants caution. A composite benefit does not establish a survival benefit. ๐Ÿ’ฌReliable pacing is the starting point. How we deliver it deserves attention. @AHAScience @NEJM #CardioCircle #CardioX #CardioTwitter #EPeeps #ScientificSessions26 #CSP #RVP #LBBP #LBBAP
1
1
97
๐Ÿšจ๐—ง๐—ต๐—ฒ ๐—”๐—œ ๐—ฑ๐—ถ๐˜ƒ๐—ถ๐—ฑ๐—ฒ๐—ป๐—ฑ ๐—บ๐—ฎ๐˜† ๐—ฏ๐—ฒ ๐˜๐—ถ๐—บ๐—ฒ. ๐ŸŸขAt #ScientificSessions26, AI drafts cut cardiologistsโ€™ echo interpretation time from 8.5 to 4.6 minutes. ๐ŸŸขSubstantial edits were needed in 50.6% of AI drafts versus 49.7% of human drafts. Cardiologists finalized every report. ๐ŸŸขThese are preliminary workflow findings; improved patient outcomes were not assessed. โžก๏ธThe next test: whether time saved reaches patients through faster reporting and better access. @HeartNews #CardioCircle #CardioX #Cardiology #CardioTwitter #MedTech #medicaldevices #Digitalhealth #AIinHealthcare
1
2
78
๐Ÿ”ด๐—ฆ๐˜๐—ผ๐—ฝ ๐—ผ๐—ฟ ๐—ฐ๐—ผ๐—ป๐˜๐—ถ๐—ป๐˜‚๐—ฒ? ๐— ๐—ฎ๐—ธ๐—ฒ ๐˜๐—ต๐—ฒ ๐—ฐ๐—ต๐—ผ๐—ถ๐—ฐ๐—ฒ ๐—ถ๐—ป๐—ณ๐—ผ๐—ฟ๐—บ๐—ฒ๐—ฑ. SAGA/SITE and STREAM studied statin discontinuation in older adults without established cardiovascular disease. Both met non-inferiority criteria, using different outcomes and follow-up. STREAM recorded more composite events after stopping. Here are the absolute numbers, comparing ๐—ฆ๐—ง๐—ข๐—ฃ versus ๐—–๐—ข๐—ก๐—ง๐—œ๐—ก๐—จ๐—˜: ๐ŸŸข๐—ฆ๐—”๐—š๐—”/๐—ฆ๐—œ๐—ง๐—˜ โžก๏ธ all-cause deaths at three years, among participants with available mortality data: โ€ข 35/484 (7.2%) versus 48/604 (7.9%). ๐ŸŸข๐—ฆ๐—ง๐—ฅ๐—˜๐—”๐—  โžก๏ธ nonfatal heart attack, nonfatal ischemic stroke or death: โ€ข First two years: 100/938 (10.7%) versus 77/942 (8.2%). โ€ข Full observed follow-up, extending up to four years: 119/938 (12.7%) versus 87/942 (9.2%). These are different endpoints and time windows; the percentages should be compared within each trial. Stopping reduces pill burden, but neither trial demonstrated better quality of life after discontinuation. Patients should understand the possible loss of cardiovascular protection, alongside uncertainty about their individual benefit. Discuss absolute risks, tolerability, life expectancy and what matters to them. Then decide together. @AHAScience #CardioCircle #CardioX #Cardiology #Statins #STREAM #AHA2026
1
1
72
๐ŸšจModerate stenosis does not always mean low stakes. #PROGRESS challenges the timing of TAVR: among 744 patients with moderate aortic stenosis and at-risk features, earlier intervention โฌ‡๏ธreduced the combined endpoint of death or heart failure events at two years. ๐ŸŸขThe benefit came from fewer heart failure events; a survival advantage was not demonstrated. Patient selection becomes the central issue. How much weight should symptoms and cardiac damage carry before the valve becomes โ€œsevereโ€โ“ @NEJM @EdwardsLifesci @crfheart nejm.org/doi/full/10.1056/NEโ€ฆ #CardioCircle #CardioX #CardioTwitter #TCT2026 #TAVR
1
2
77
Where should the stent landโ‰๏ธ In P4, planning started on coronary CT. CT-guided PCI was noninferior to IVUS-guided PCI for 1-year target-vessel failure (4.1% vs 4.6%). Median PCI time was 46 vs 63 min. @ColletCarlos @NEJM @crfheart #TCT2026 #CardioCircle #CardioX #CardioTwitter #CCTA doi.org/10.1056/NEJMoa261077โ€ฆ
2
3
176
Important conversations on the role of: 1) @FDA EFS & FIH trials 2) #MedTech in improving access to innovations ๐Ÿ’กInnovation ๐Ÿ‘‰Implementation โ€œIt takes an average of 17 years for medtech solutions to reach practiceโ€ #PeterFitzgerald ๐Ÿ’กCV care will exceed 1Trillion ๐Ÿ’ต by 2030 ๐Ÿ’กGBD: Efficacy of vaccines 80-90% & current management of hypertension reaches only 25%
2
9
12
1,329
๐ŸšจValve care cannot stop at a successful implant. Closing a heart valve leak without another open-heart operation. Paracloseโ€™s value lies in what it may spare suitable patients: another open-heart operation. @AbbottNews announced FDA approval for Paraclose, a catheter-delivered plug for leaks around surgical replacement valves. How we manage the next intervention belongs in our definition of success. #CardioCircle #CardioX #CardioTwitter #StructuralHeart #MedTech
2
1
3
164
๐—ง๐—–๐—ง ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ: ๐Ÿญ๐Ÿฎ ๐˜๐—ฟ๐—ถ๐—ฎ๐—น๐˜€ ๐˜๐—ผ ๐˜„๐—ฎ๐˜๐—ฐ๐—ต. Coronary imaging, valve intervention, antithrombotic therapy, and renal denervation are all on our radar. ๐Ÿ“ San Diego | 31 Octoberโ€“3 November From Cardiovascular Research Foundationโ€™s program (@crfheart), hereโ€™s CardioCircleโ€™s watchlist: ๐—ฆ๐—จ๐—ก๐——๐—”๐—ฌ โ€ข ๐Ÿญ ๐—ก๐—ข๐—ฉ๐—˜๐— ๐—•๐—˜๐—ฅ ๐Ÿ”น P4 โžก๏ธ Coronary CT versus IVUS to guide PCI. @ColletCarlos ๐Ÿ”น TRANSFORM II โžก๏ธ Sirolimus-coated balloons challenge everolimus-eluting stents. @BernardoCortese @conceptmedicals ๐Ÿ”น HD-PCI โžก๏ธ Finding the right heparin dose during PCI. ๐Ÿ”น REMEDY-PILOT โžก๏ธ A sham-controlled test of a coronary sinus reducer for refractory angina without obstructive coronary disease. @JNJMedTech @ShockwaveIVL ๐Ÿ”น TRAVEL III โžก๏ธ LuX-Valve Plus replacement versus medical therapy for severe tricuspid regurgitation. ๐— ๐—ข๐—ก๐——๐—”๐—ฌ โ€ข ๐Ÿฎ ๐—ก๐—ข๐—ฉ๐—˜๐— ๐—•๐—˜๐—ฅ ๐Ÿ”น PROGRESS โžก๏ธ Earlier TAVR for selected patients with moderate aortic stenosis. @PhilGenereuxMD ๐Ÿ”น CLASP II TR โžก๏ธ What #PASCAL repair adds to medical therapy for severe, symptomatic tricuspid regurgitation. @EdwardsLifesci ๐Ÿ”น SIMPLAAFY โžก๏ธ Simplifying antithrombotic treatment after left atrial appendage closure. @bostonsci ๐—ง๐—จ๐—˜๐—ฆ๐——๐—”๐—ฌ โ€ข ๐Ÿฏ ๐—ก๐—ข๐—ฉ๐—˜๐— ๐—•๐—˜๐—ฅ ๐Ÿ”น PIONEER IV โžก๏ธ Using angiography-derived coronary physiology to guide PCI. ๐Ÿ”น EPIC17-VERONICA โžก๏ธ Platelet testing to guide antiplatelet de-escalation after acute coronary syndromes. ๐Ÿ”น SPYRAL AFFIRM โžก๏ธ US post-approval evidence for radiofrequency renal denervation. @Medtronic @Kandzari ๐Ÿ”น PROTEMBO IDE โžก๏ธ Testing cerebral embolic protection during TAVR. #protembis These upcoming presentations could inform patient selection, procedural choices, and the balance between benefit and harm. Which trial is highest on your watchlist, @TCTMDโ‰๏ธ @PCRonline @TCTConference @HeartFlow @Cleerly @ElucidBio @SiemensHealthES #CardioCircle #TCT2026 #CardioX #InterventionalCardiology #StructuralHeart #TAVR #PCI #DrugCoatedBalloons #LAAO #RenalDenervation #ClinicalTrials #MedTech #Cardiology #P4 #CTguidedPCI #CCTA #ANOCA
1
4
296
Free tools built by clinicians for learning the many facets of cardiology๐Ÿซ€๐Ÿฉปโšก๏ธ๐Ÿงฎ๐Ÿ“š๐Ÿ•น๏ธ Explore these resources๐Ÿ‘‡๐Ÿผ: ๐ŸฉปEchocardiography: intro2echo.com by @David_Ouyang ๐ŸฉปAngiography Views: angioview.com by @AnnasRahmanMD โšก๏ธLocalize PVCs: learnpvcs.com by @Challa1218 โšก๏ธLocalize VTs: simvt.vercel.app by @ArunUMahtani โšก๏ธLBBAP Simulator: pacingsimulator.com by @jo3_assad ๐ŸฉปLAA TEE/ICE/CT Simulator: laa.liorjankelson.com by @ExtraStim ๐ŸงฎInteractive Core Cardiology Tools and Calculators: tools.rueyhu.com by @ruey_hu ๐Ÿ“šLatest Trials and Guidelines: cardiolads.com by Jay Gohri, Adhish Beri, and @KochharGunjan ๐ŸฉปInteractive M Mode: pulmonarypocus.com by @HoosierPocus ๐Ÿ•น๏ธNight Float Simulator: cardsnightfloat.netlify.app by @AbedfromBeirut ๐Ÿ•น๏ธCongenital Heart Disease, Pacemaker, ECG Simulators: cardiorender.com by Dinesh Raja P This list keeps growing. Know a free, clinician-built tool that belongs here? Drop the link below #Cardiology #CardioTwitter #MedEd #MedTwitter #FOAMed #VibeCoding #AI #AIinMedicine #LLMs #DigitalHealth @ACCinTouch @escardio @ASE360 @Heart_SCCT @HRSonline @SCAI @CardioNerds
33
204
4
592
43,893
๐—ง๐—ต๐—ฒ ๐˜€๐˜๐—ฒ๐˜๐—ต๐—ผ๐˜€๐—ฐ๐—ผ๐—ฝ๐—ฒ ๐—ด๐—ฒ๐˜๐˜€ ๐—ฎ๐—ป ๐—”๐—œ ๐˜‚๐—ฝ๐—ด๐—ฟ๐—ฎ๐—ฑ๐—ฒ. @Eko_Healthโ€™s #FDA-cleared CORE 300 combines analog listening with up to 35ร— digital amplification, noise cancellation, and a heart-rate display. Connect it to the Eko App with Eko+ membership for AI-supported structural murmur detection. Our take: fitting AI into a familiar bedside tool could make adoption easier. Its clinical value will depend on how those findings guide further evaluation and care. Would you add AI to your stethoscopeโ‰๏ธ #CardioCircle #CardioX #CardioTwitter #MedTech #medicaldevices #Digitalhealth #AIinHealthcare
1
1
3
147
๐—ง๐˜„๐—ผ ๐—น๐—ฒ๐—ฎ๐—ฑ๐˜€. ๐—”๐˜๐—ฟ๐—ถ๐—ฎ๐—น ๐˜€๐—ฒ๐—ป๐˜€๐—ถ๐—ป๐—ด. ๐—ฅ๐—ฒ๐˜€๐˜†๐—ป๐—ฐ๐—ต๐—ฟ๐—ผ๐—ป๐—ถ๐˜‡๐—ฎ๐˜๐—ถ๐—ผ๐—ป. #BIOTRONIK announced the first US Acticor Sky CRT-DX implant, performed by Dr. Niraj Varma at @ClevelandClinic. DX technology enables atrial sensing within a two-lead CRT-D system. The platform also includes HeartInsight alerts for worsening heart failure. The practical attraction: less implanted hardware while retaining atrial information in appropriately selected patients. A first implant marks adoption; comparative clinical value requires evidence. Which patients would you consider the best candidates for this approach in your practiceโ‰๏ธ @BIOTRONIK_News #CardioCircle #CardioX #CardioTwitter #EPeeps #HeartFailure #MedTech
1
3
139
๐—” ๐—ป๐—ฎ๐˜€๐—ฎ๐—น ๐˜€๐—ฝ๐—ฟ๐—ฎ๐˜† ๐—ณ๐—ผ๐—ฟ ๐—”๐—™ ๐—ฟ๐—ฎ๐˜๐—ฒ ๐—ฐ๐—ผ๐—ป๐˜๐—ฟ๐—ผ๐—น? ๐ŸšจMilestoneโ€™s ReVeRA-301 Phase 3 trial has expanded into Europe. It tests self-administered #etripamil for symptomatic AF with rapid ventricular rate, measuring rate reduction within 30 minutes and symptom improvement. CARDAMYST is #FDA-approved for acute symptomatic PSVT in adults. AF use remains investigational. ๐ŸŸขThe question is compelling: could selected patients eventually manage these episodes outside hospital under a prescribed treatment planโ‰๏ธ Phase 3 results must establish the benefit and safety of this approach. @MIST_Milestone #CardioCircle #CardioTwitter #CardioX #medX #AFib
1
2
148
๐Ÿšจ๐—ฅ๐—ฒ๐—ฝ๐—ฎ๐—ถ๐—ฟ ๐˜๐—ต๐—ฒ ๐—น๐—ฒ๐—ฎ๐—ธ. ๐—œ๐—บ๐—ฝ๐—ฟ๐—ผ๐˜ƒ๐—ฒ ๐—ผ๐˜‚๐˜๐—ฐ๐—ผ๐—บ๐—ฒ๐˜€. In TRIC-I-HF, transcatheter tricuspid repair added to medical therapy lowered the hazard of death or heart-failure hospitalization in selected high-risk patients with severe tricuspid regurgitation. HR: 0.40 through three years. #PASCAL and #TriClip were the main repair systems used. The trial evaluated an intervention strategy, not which device is superior. For structural-heart teams and industry, the focus now includes patient selection, referral pathways, and delivery of treatment. How should this evidence change your heart-team discussionโ‰๏ธ #CardioCircle #CardioX #CardioTwitter #MedTech #StructuralHeart
1
1
2
123
๐Ÿšจ๐—ช๐—ต๐—ถ๐—ฐ๐—ต ๐—ป๐—ฎ๐—ฟ๐—ฟ๐—ผ๐˜„๐—ถ๐—ป๐—ด ๐—ป๐—ฒ๐—ฒ๐—ฑ๐˜€ ๐—ฎ ๐˜€๐˜๐—ฒ๐—ป๐˜? AIR-STEMI used angiography-derived physiology to guide non-culprit PCI after successful culprit treatment in STEMI. ๐ŸŸขThe primary composite- death, MI, stroke, or ischemia-driven revascularization- was lower: 8.9% vs 13.7%. ๐ŸŸขFewer non-culprit vessels received PCI. ๐Ÿ”ดMortality alone was not significantly reduced. The technology story: software can turn angiographic images into information that changes treatment decisions. The implementation question: can cath labs reproduce this core-lab-supported strategy in everyday practiceโ‰๏ธ #CardioCircle #CardioTwitter #CardioX #InterventionalCardiology #MedTech
1
3
135
๐Ÿšจ๐—™๐—ผ๐˜‚๐—ฟ ๐—บ๐—ฒ๐—ฑ๐—ถ๐—ฐ๐—ถ๐—ป๐—ฒ๐˜€. ๐—ข๐—ป๐—ฒ ๐—ฐ๐—ฎ๐—ฝ๐˜€๐˜‚๐—น๐—ฒ. A heart-failure polypill combines #bisoprolol, #losartan, #eplerenone, and #dapagliflozin. In a 40-patient randomized pilot, pill-count adherence at four weeks was better than with usual care: 85% versus 47% took at least 80% of their doses. Promising for simplifying treatment, but this small, short study does not establish fewer hospitalizations or deaths. Could reducing pill burden help more patients stay on foundational heart-failure therapy? The next challenge: preserving flexibility to adjust each medicine while making treatment easier to follow. #CardioCircle #CardioTwitter #CardioX #medX #HeartFailure
3
1
6
374